{"title":"Small Extracellular Vesicles in the Pericardium Modulate Macrophage Immunophenotype in Coronary Artery Disease","authors":"Soumaya Ben-Aicha PhD , Maryam Anwar PhD , Gemma Vilahur PhD , Fabiana Martino PhD , Panagiotis G. Kyriazis MSc , Natasha de Winter MSc , Prakash P. Punjabi MD, PhD , Gianni D. Angelini MD , Susanne Sattler PhD , Costanza Emanueli PhD","doi":"10.1016/j.jacbts.2024.05.003","DOIUrl":"10.1016/j.jacbts.2024.05.003","url":null,"abstract":"<div><div>Coronary artery disease (CAD) is a major health issue. This study focused on pericardial macrophages and small extracellular vesicles (sEVs) in CAD. The macrophages in CAD patients showed reduced expression of protective markers and unchanged levels of proinflammatory receptors. Similar changes were observed in buffy-coat–derived macrophages when stimulated with CAD pericardial fluid-derived sEVs. The sEV contained miRNA-6516-5p, which inhibited CD36 and affected macrophage lipid uptake. These findings indicate that sEV-mediated miRNA actions contribute to the decrease in protective pericardial macrophages in CAD.</div></div>","PeriodicalId":14831,"journal":{"name":"JACC: Basic to Translational Science","volume":"9 9","pages":"Pages 1057-1072"},"PeriodicalIF":8.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2452302X24001888/pdfft?md5=a5069912a4a92134ebda4433d621f0d5&pid=1-s2.0-S2452302X24001888-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141703465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Douglas L. Mann MD (Editor-in-Chief, JACC: Basic to Translational Science)
{"title":"The Use of Digital Healthcare Twins in Early-Phase Clinical Trials","authors":"Douglas L. Mann MD (Editor-in-Chief, JACC: Basic to Translational Science)","doi":"10.1016/j.jacbts.2024.08.002","DOIUrl":"10.1016/j.jacbts.2024.08.002","url":null,"abstract":"","PeriodicalId":14831,"journal":{"name":"JACC: Basic to Translational Science","volume":"9 9","pages":"Pages 1159-1161"},"PeriodicalIF":8.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2452302X24002936/pdfft?md5=cb67a842585465ea6128136fadae1e91&pid=1-s2.0-S2452302X24002936-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142310567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"“Circulating Inflammation” and the Plasma Proteome in Heart Failure With Preserved Ejection Fraction","authors":"Thomas M. Vondriska PhD , David J. Lefer PhD","doi":"10.1016/j.jacbts.2024.07.004","DOIUrl":"10.1016/j.jacbts.2024.07.004","url":null,"abstract":"","PeriodicalId":14831,"journal":{"name":"JACC: Basic to Translational Science","volume":"9 9","pages":"Pages 1085-1087"},"PeriodicalIF":8.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2452302X24002614/pdfft?md5=3cfd1d18ff0b9c640a8524bcd25ab645&pid=1-s2.0-S2452302X24002614-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142310561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"TRIM55: An Enemy at the Post-MI Border?","authors":"Marco Andreis MD , Nazareno Paolocci MD, PhD","doi":"10.1016/j.jacbts.2024.06.009","DOIUrl":"10.1016/j.jacbts.2024.06.009","url":null,"abstract":"","PeriodicalId":14831,"journal":{"name":"JACC: Basic to Translational Science","volume":"9 9","pages":"Pages 1123-1125"},"PeriodicalIF":8.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2452302X24002547/pdfft?md5=de6282ef3290f001d32447e932b42c89&pid=1-s2.0-S2452302X24002547-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142310565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Virginia S. Hahn MD , Senthil Selvaraj MD, MS, MA , Kavita Sharma MD , Svati H. Shah MD, MHS
{"title":"Towards Metabolomic-Based Precision Approaches for Classifying and Treating Heart Failure","authors":"Virginia S. Hahn MD , Senthil Selvaraj MD, MS, MA , Kavita Sharma MD , Svati H. Shah MD, MHS","doi":"10.1016/j.jacbts.2024.04.008","DOIUrl":"10.1016/j.jacbts.2024.04.008","url":null,"abstract":"<div><div>Both heart failure and cardiometabolic disease are on the rise, and abnormal cardiac and peripheral metabolism are central to the syndrome of heart failure. Advances in metabolomic profiling have improved our understanding of the heart’s metabolic flexibility in patients with and without heart failure. Prior studies have noted patients with heart failure display metabolomic profiles associated with marked abnormalities in the metabolism of fatty acids, branched-chain amino acids, ketones, and glucose compared with control subjects. Metabolomics can highlight specific pathways that are dysregulated; however, other metabolites beyond those related to fuel metabolism may also play a role in precision-medicine approaches. Novel approaches include metabolic flux studies, spatial and single-cell analysis, serial monitoring of treatment response, and integration with other -omics data. The goal of these innovative approaches should be to harness metabolomic technologies to affect precision care for patients with heart failure.</div></div>","PeriodicalId":14831,"journal":{"name":"JACC: Basic to Translational Science","volume":"9 9","pages":"Pages 1144-1158"},"PeriodicalIF":8.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2452302X24001773/pdfft?md5=38912ce373f5c15c65c5656b08679e0b&pid=1-s2.0-S2452302X24001773-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142248659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The Imperative to Enhance Cost-Effectiveness for Cardiovascular Therapeutic Development","authors":"","doi":"10.1016/j.jacbts.2023.12.005","DOIUrl":"10.1016/j.jacbts.2023.12.005","url":null,"abstract":"<div><p>Cardiovascular disease (CVD) is the leading cause of mortality worldwide. Therapeutic agents, such as those that lower low-density lipoprotein cholesterol, have been a critical factor in mitigating CVD event risk and demonstrate the important role that drug discovery plays in reducing morbidity and mortality. However, rapidly rising development costs, diminishing returns, and an increasingly challenging regulatory environment have all contributed to a declining number of cardiovascular (CV) therapeutic agents entering the health care marketplace. For pharmaceutical companies, a traditional cardiovascular outcomes trial (CVOT) can be a major financial burden and impediment to CV agent development. They can take as long as a decade to conduct, delaying potential investment return while carrying risk of failure. For patients, lengthy CVOTs delay drug accessibility. Without cost-effective CVOTs, drug innovation may be compromised, with CV patients bearing the consequences. This paper reviews potential approaches for making CV drug development more cost-effective.</p></div>","PeriodicalId":14831,"journal":{"name":"JACC: Basic to Translational Science","volume":"9 8","pages":"Pages 1029-1040"},"PeriodicalIF":8.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2452302X24000020/pdfft?md5=f9f873ce4a3421c7208a6be748dfe0f2&pid=1-s2.0-S2452302X24000020-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139919724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Reassessing the Mechanisms of PLN-R14del Cardiomyopathy","authors":"","doi":"10.1016/j.jacbts.2024.02.017","DOIUrl":"10.1016/j.jacbts.2024.02.017","url":null,"abstract":"<div><p>The phospholamban (PLN) pathogenic gene variant, p.Arg14del (PLN-R14del), can lead to dilated and arrhythmogenic cardiomyopathy, resulting in heart failure. PLN-R14del cardiomyopathy has been conceptualized as a disease caused by sarco/endoplasmic reticulum calcium adenosine triphosphatase 2a (SERCA2a) superinhibition. However, recent studies raised controversy regarding the effect of PLN-R14del on SERCA activity and revealed a prominent role for abnormal PLN protein distribution and sarco/endoplasmic reticulum disorganization as underlying disease mechanism. Strategies targeting sarco/endoplasmic reticulum malformation may, therefore, prove more effective than SERCA activity modulation. This review reassesses the disease mechanisms of PLN-R14del cardiomyopathy and emphasizes the importance of dissecting the underlying molecular mechanisms to uncover targets for innovative treatments.</p></div>","PeriodicalId":14831,"journal":{"name":"JACC: Basic to Translational Science","volume":"9 8","pages":"Pages 1041-1052"},"PeriodicalIF":8.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2452302X24000962/pdfft?md5=bcabe0e2e6fb2ba5c06431d948285875&pid=1-s2.0-S2452302X24000962-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140793502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}